Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for your reply SOG
Good morning Gunner. My 6 months would start from granting of clinical trial. So yes l can be seen to look a bit optimistic by saying 6 months from now. I apologise for that.
Phase 1 trials for toxicity in humans should not take long . A small number of healthy volunteers given an escalating dose from 12.5 mg per day and then increased
Not sure how high the first recruitment will go to, maybe 50 to 100 mg per day. Short period of time then it is repeated with healthy set of new volunteers that start on maybe 50 to 100 mg per day then increase dose daily. This will continue until.toxicity develops or we have well exceeded 1000 mg per day.
These early tests take around 5 to 6 months l believe. Should not have to wait as long as we did for toxicity results of preclinical l am surmising.
Stage 2 trials will be the treatment of an indication in a small number of people with an ailment. First thing looked at is, is it more effective than current forms of treatment and are there any side affects? This one will take longer likely around a year.
Now if toxicity is not an issue and we can deliver to a human around 1000 mg a day with no adverse effects, then l believe we will have proven to have ****ed all over anything else currently out there
Toxicity will reduce the amount of a compound that can be administered to a human. It is ok to say a compound will treat Indications but to do so must be delivered in adequate quantities. Toxicity restricts that. Toxicity issues are a primary reason for a drug failure.
Apologies for rambling on. Should Sareum start early July we will know within 6 months if we have cracked it or not. Taking your CTA application and capsule formulation timescales along with the red tape of approx 3 months, that appear very realistic and down to earth, we are looking at 9 to 10 months from now.
So yes, 6 months from now rather optimistic. I will go for 9 to 12 months from now which is not far away from your 18 months.
Also bare in mind that anytime before this offers can be made for license or whatever.
Regards.
Ps if it seems a bit hickledy pickledy then I am blaming my little mob phone.
Regards
Gunner - I’m fairly sure you cannot apply for Agile funding until you provide evidence of clinical low toxicity results.
The more I think about it, It could make some sense for GSK to come after Sareum sooner rather than later. SRA 737 would all be under one roof - Sareum’s licence deal is still lucrative enough to be seen as a valuable acquisition. SDC1801 is at the stage now where pharmas have to make a decision to whether to make an offer early in the hope of getting a better deal. GSK are active in seeking to develop more pipeline assets and they have got the cash to spend. Why wait and risk a more expensive deal later for SDC1801 when you can maybe bag SRA 737 and SDC 1801.in one big deal. Pure conjecture on my part. But the pattern of trading over the last month or so suggests to me that something is up.
SOG do you really think 6 months or have I miss understood I’d say at least 18 months for results to be announced from now we haven’t had confirmation for completion of the capsule and until that is complete no CTA will be filed then another 2 months to be granted and maybe if lucky trials of ph1 will start nov dec and by the time it’s finished and results announced will be another 9 months just look how long the tox results took . Hope I’m wrong but SAR isn’t exactly the rushing type of company and we’ve had 3 months with no word of possible Agile funding
GLA
Good evening Elcap. I am of a similar opinion to yourself. GSK claim to have made offer to Sierra for Momo for 1.9 billion. In the pipeline they have 737 and 515.
The board of Sierra invested quite heavily at end of last year in shares. They are guaranteed a healthy profit from the circa 15 dollars per share they bought in at.
Directors will want deal to go through
Momo will be marketed in a comparatively small niche market. The market for a Chk1 inhibitor especially in combo with the likes of 515 is inherently much larger. Bare in mind that SDC 1802 can be used in conjunction with a CHK 1 inhibitor as well as also a myriad of other treatments to improve effectiveness and compensate for cancer that develops resistance to treatments.
That being said l can see no reason as to why Sierra/ GSK want to create positive publicity around 737 or to a lesser extent 515.
GSK/ Sierra will not want a competitor coming in and trumping their offer at the last minute. Hence l believe why the 737 profile has been kept so low for the past 6 months. Finalising trial design they say! You scratch h my back and l will scratch yours comes to mind here.
I don't see much happening with news of 737 or any change in the stagnant 55 dollar Sierra share price until deal is finalised. I would hazard a guess however, that the designs are in place and if and when deal is finalised 737 development will.be rapidly propelled forwards.
In all we have held up well with SP compared to many other companies. Yes we can drift down a tad on no news but can climb rapidly on good. The one to watch for is results for our SDC1801 phase 1 trial in human clinical toxicity studies. That is the biggy. As this milestone is reached, then we will be in a position to command licensing conditions and payments both up front and on royalties. What are we looking at for that to recevie positive news via an RNS updating progress.? 6 months or there abouts.
In the meantime all we can realistically do is wait.
Elcap - FWIW agree with you 100%
I'm not into name calling or ****ging others off. IMHO Sierra were never going to progress SRA737 until after momo. However I think GSK know exactly what they are getting. SRA737 will be very much kept on the 'down low' until the GSK/Sierra deal is fully signed off and complete. GSK will then progress SRA737 immediately. Why wouldn't they. GSK have a completely different mindset, agenda (and funds) to that of Sierra. So until the deal is complete GSK and Sierra will blank us completely. What would be interesting is if a) the GSK/Sierra deal falls through. (I could then see GSK making an approach to Sierra for SRA737). b) Deal goes through and GSK then come after SAR completely. c) Deal fails and GSK just decide to come after SAR completely.
IMO all options are positive for SAR. But nothing is going to happen until deal completes or falls apart.
Only other scenarios are d) A N Other Pharma tries to step in for SAR under GSK's nose or the most unlikely of all the options e) SAR continue to progress SDC1801/1802 all the way throughto end of P3 trials. Even this option leads to the promised land (presuming both molecules are successful), it will just take another 5yrs.
We are now in a holding pattern until deal is done / or fails. So probably another couple of months of stagnation, unless we get positive news on patents etc or more invbestment from HNWI's.
I'm remaining patient, although offer accepted on new house, so could really do with SAR releasing some very positive news inside the next 6 weeks.
COME ON SAR!!!!! Throw me a bone here.
AIMHO GLA DYOR
Elcap
On this point Cobalt I’d have to agree with you, bit of a mystery why there are not more PI investing, no large II as of yet and no share options being released for those NED’s that are not fully loaded up. Knowledge of what is relevant to Sar is not the exclusive domain of posters on this bb. I too am equally surprised but AIM thrives on news so the patient wait continues.
Bobbler. My very much loved Mother died 14 years ago this week and she is much missed to this day. It pretty low to make assumptions about my childhood and why I post on this forum. I hope even people who think very little of me will think you've posted in very poor taste.
It’s a dog share no one wants it. Going no where, pointless purchase etc etc etc……..
That’s why your on here moaning about it…. You claim to be invested in it…..
What bit makes sense????
Mummy why didn’t you show me more love? If you had I wouldn’t have to go on the BB and try to annoy people with my negativity.
If you don’t like the performance, just sell up and move on.
outside of the group, it is hardly ever mentioned, primarily because the specific news to SAR are so few and far between. plus, the rampy rise of the HNWI's pushed the price so high as to be massively overbought, both by retailers AND the HNWIs (regardless of what everyone says about their 'knowledge, only the first two are actually in the black on this one) so who is going to be interested in a share that has mad multiples predicted within a closed group that are deeply suspicious of any new posters unless they're fauningly obsessive about the future, based on the mad multiples that the HNWIs bought and inflated.
Anybody explain why nobody is interested in buying Sareum shares atm? Apart from the usuals on here, Sareum remains off the radar. Just an observation based on facts and not hype and conjecture.